Interview with a Patients' Advocate

Acta Haematol. 2020;143(1):1-4. doi: 10.1159/000502731. Epub 2019 Oct 7.
No abstract available

Publication types

  • Interview

MeSH terms

  • Disease Management
  • Humans
  • Imatinib Mesylate / adverse effects
  • Imatinib Mesylate / therapeutic use
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
  • Patient Advocacy*
  • Physician-Patient Relations

Substances

  • Imatinib Mesylate